Instrument Inactif

Communiqués KARA THER

Actions

KRTX

US48576A1007

Communiqués

18/03/24	KARA THER : Acquisition/Asset Disposal - Form 8-K	PU
01/03/24	Karuna Therapeutics : Material Event - Form 8-K	PU
22/02/24	Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update	BU
14/02/24	KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX	BU
31/12/23	KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX	BU
22/12/23	Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio	AQ
22/12/23	BMS strikes $14bn deal for Karuna Therapeutics	AQ
15/12/23	Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia	BU
29/11/23	Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia	BU
16/11/23	Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia	BU
02/11/23	Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates	BU
01/11/23	Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress	BU
01/11/23	Karuna Therapeutics to Present at Upcoming Investor Conferences	BU
19/10/23	Karuna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023	BU
05/10/23	Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology Congress	AQ
04/10/23	Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) Congress	BU
28/09/23	Karuna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of Schizophrenia	BU
30/08/23	Karuna Therapeutics to Present at Upcoming Investor Conferences	BU
03/08/23	Karuna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business Updates	BU
03/08/23	Karuna Therapeutics Announces Leadership Appointments	BU
20/07/23	Karuna Therapeutics to Announce Second Quarter 2023 Financial Results and Provide General Business Update on Thursday, August 3, 2023	BU
30/05/23	Karuna Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference	BU
22/05/23	Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting	BU
04/05/23	KARUNA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
04/05/23	Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business Updates	BU